Drug intelligence / Profile preview

modafinil

Development stage
Approved
Lead developer
Teva Pharmaceutical Industries
Modality
Small Molecules
Administration
Oral
01

Overview

Modafinil is a wakefulness-promoting agent and central nervous system (CNS) stimulant used primarily to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS), and shift work sleep disorder. It is a racemic compound taken orally, available as 100 mg and 200 mg tablets. The precise mechanism of action remains unclear, but modafinil is believed to promote wakefulness by altering the concentrations of certain neurotransmitters in the brain—primarily through inhibition of dopamine reuptake via binding to the dopamine transporter, leading to increased extracellular dopamine levels. It may also activate orexin neurons in the hypothalamus and influence glutamatergic circuits while inhibiting GABAergic activity. Unlike traditional stimulants such as amphetamines, modafinil has a distinct chemical structure and lower potential for euphoria or abuse but is still classified as a Schedule IV controlled substance due to some risk of misuse[1][2][3][4][5][6].

Brand names
Provigil
Other names
莫达非尼ModafiniloModafinilum
02

Targets

SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)ADRA1B (α1B)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on modafinil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on modafinil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call